Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for SGLT1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery | SGLT1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Essential for multi-pass transmembrane protein expression. |
View SGLT1 Products |
| Antigen (ECD-Fc) | SGLT1 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Theoretical MW. |
View SGLT1 Products |
| Antigen (Membrane Preparation) | SGLT1 Membrane Preparation High purity (>90%), Sequence Verified, Endotoxin <1EU/ug. |
View SGLT1 Products |
| Benchmark Ab | Anti-SGLT1 (Biosimilar Sequence) Recombinant positive control for expression validation and flow cytometry. |
View SGLT1 Products |
| Validator | SGLT1 siRNA Set For knockdown verification in functional assays. |
View SGLT1 Products |
| Multi-species Panel | SGLT1 Lentivirus Premade Particles (Human/Mouse/Rat/Cyno) For species translation studies. |
View SGLT1 Products |
| Mutant Variants | SGLT1 Mutant Proteins (GGM-associated mutations rs121912669, rs121912668, rs17683011) For functional rescue and disease modeling. |
View SGLT1 Products |
| Related Target A | SGLT2 (SLC5A2) Primary counter-screening target for dual SGLT1/2 inhibitor development. |
View SGLT2 Products |
| Related Target B | GLP-1R Synergistic pathway for metabolic and obesity combination therapies. |
View GLP-1R Products |
| Related Target C | GLUT2 (SLC2A2) Facilitative glucose transporter for pathway synergy analysis. |
View GLUT2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Complex 14-Transmembrane Domain Conformation | Lentivirus-Based Stable Cell Lines to preserve native topology |
| Subfamily Counter Screening (vs SGLT2) | Sequence Verified human SGLT2 ortholog available |
| Lack of Controls | Clinical Benchmark Antibodies and siRNA included |
| Species Translation (Human to Rodent/Cyno) | Multi-species SGLT1 Lentivirus Panel |
| Functional Uptake Validation | High-Expression Cell Lines compatible with radioactive glucose uptake assays |
Live SGLT1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SGLT1 therapeutics is intensifying, with major players shifting focus from traditional mono-therapies to Dual SGLT1/2 inhibitors and metabolic combinations. As first-generation therapies like sotagliflozin secure regulatory approvals for heart failure, the next wave of R&D is targeting optimal SGLT1 vs SGLT2 selectivity ratios to maximize glycemic control while managing gastrointestinal side effects. Tissue-specific strategies, such as GI-restricted SGLT1 inhibition for obesity management, are gaining traction. Concurrently, gene therapy approaches for Congenital Glucose-Galactose Malabsorption (GGM) are entering preclinical development, requiring functional rescue assays using mutant SGLT1 variants.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Dual SGLT1/2 Inhibitors (Small Molecule) | Lexicon, Sanofi | Type 1 Diabetes, Heart Failure | Selectivity Assay (Need SGLT2 ortholog protein for counter-screening) |
| GI-Restricted Inhibitors | Novo Nordisk | Obesity, Metabolic Syndrome | Intestinal Cell Models (Need polarized epithelial cell lines with SGLT1) |
| Gene Therapy | Ultragenyx (pipeline) | Congenital Glucose-Galactose Malabsorption | Functional Rescue Assays (Need mutant SGLT1 variants) |
| Peptide/mAb | Early-stage biopharma | Obesity, Metabolic Syndrome | Binding Assay (Need Lentivirus for cell-based Flow Cytometry) |
Key Mutations and Genetic Variants
SGLT1 (SLC5A1) mutations cause congenital glucose-galactose malabsorption (GGM). Key mutations supported by UniProt (P13866) include:
- rs121912669 (in GGM): loss-of-function variant.
- rs121912668 (in GGM): loss-of-function variant.
- rs17683011 (in GGM, slightly decreased activity): hypomorphic variant.
These variants are critical for developing gene therapy rescue assays and studying genotype-phenotype correlations. TarMart provides mutant SGLT1 proteins and lentivirus constructs for these specific variants.
Related Targets & Cross-Selling Opportunities
To support combination therapy and selectivity screening, the following targets are recommended:
- SGLT2 (SLC5A2): Mandatory for counter-screening in dual inhibitor programs.
- GLP-1R: For metabolic and obesity combination therapies.
- GLUT2 (SLC2A2): Facilitative glucose transporter for pathway synergy analysis.